Literature DB >> 27469369

Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications.

Patrick A Hughes1, Samuel P Costello2, Robert V Bryant3, Jane M Andrews3.   

Abstract

Opioids are one of the most prescribed drug classes for treating acute pain. However, chronic use is often associated with tolerance as well as debilitating side effects, including nausea and dependence, which are mediated by the central nervous system, as well as constipation emerging from effects on the enteric nervous system. These gastrointestinal (GI) side effects limit the usefulness of opioids in treating pain in many patients. Understanding the mechanism(s) of action of opioids on the nervous system that shows clinical benefit as well as those that have unwanted effects is critical for the improvement of opioid drugs. The opioidergic system comprises three classical receptors (μ, δ, κ) and a nonclassical receptor (nociceptin), and each of these receptors is expressed to varying extents by the enteric and intestinal extrinsic sensory afferent nerves. The purpose of this review is to discuss the role that the opioidergic system has on enteric and extrinsic afferent nerves in the lower GI tract in health and diseases of the lower GI tract, particularly inflammatory bowel disease and irritable bowel syndrome, and the implications of opioid treatment on clinical outcomes. Consideration is also given to emerging developments in our understanding of the immune system as a novel source of endogenous opioids and the mechanisms underlying opioid tolerance, including the potential influence of opioid receptor splice variants and heteromeric complexes.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  immune; inflammatory bowel diseases; irritable bowel syndrome; nervous system; opioid

Mesh:

Substances:

Year:  2016        PMID: 27469369     DOI: 10.1152/ajpgi.00442.2015

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  7 in total

Review 1.  Opioid misuse in gastroenterology and non-opioid management of abdominal pain.

Authors:  Eva Szigethy; Mitchell Knisely; Douglas Drossman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-15       Impact factor: 46.802

2.  µ-opioid receptor, β-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients.

Authors:  Giovanni Dothel; Lin Chang; Wendy Shih; Maria Raffaella Barbaro; Cesare Cremon; Vincenzo Stanghellini; Fabrizio De Ponti; Emeran A Mayer; Giovanni Barbara; Catia Sternini
Journal:  Neurogastroenterol Motil       Date:  2019-07-23       Impact factor: 3.598

Review 3.  Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice.

Authors:  Ana Fernández-Montes; Guillermo de Velasco; Santiago Aguín; Cristina Farriols; María Guirado-Risueño; Vanessa G Jerviz-Guía; María Victoria Baeza-Nadal; Rodolfo Chicas-Sett; José Luis Fírvida; Francisco García-Navalón; Patricia Martín; Carmen Perezagua-Marín; Dulce Rodríguez; Joan Santamaría; Tamara Saurí; Manuel Cobo
Journal:  Curr Treat Options Oncol       Date:  2021-02-26

4.  Precision Lactobacillus reuteri therapy attenuates luminal distension-associated visceral hypersensitivity by inducing peripheral opioid receptors in the colon.

Authors:  Shrilakshmi Hegde; You-Min Lin; Yu Fu; Tor Savidge; Xuan-Zheng Shi
Journal:  Pain       Date:  2020-12       Impact factor: 7.926

5.  Delta opioid receptors on nociceptive sensory neurons mediate peripheral endogenous analgesia in colitis.

Authors:  Xavier Mas-Orea; Lilian Basso; Catherine Blanpied; Claire Gaveriaux-Ruff; Nicolas Cenac; Gilles Dietrich
Journal:  J Neuroinflammation       Date:  2022-01-06       Impact factor: 8.322

6.  The effects of fentanyl, oxycodone, and butorphanol on gastrointestinal function in patients undergoing laparoscopic hysterectomy: a prospective, double-blind, randomized controlled trial.

Authors:  Minna Guo; Shijiang Liu; Jian Gao; Chuanbao Han; Chun Yang; Cunming Liu
Journal:  BMC Anesthesiol       Date:  2022-02-24       Impact factor: 2.217

Review 7.  Naldemedine: A New Option for OIBD.

Authors:  Flaminia Coluzzi; Maria Sole Scerpa; Joseph Pergolizzi
Journal:  J Pain Res       Date:  2020-05-26       Impact factor: 3.133

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.